Background In trials of patients with left ventricular dysfunction or heart failure, ACE inhibitor
use was unexpectedly associated with reduced myocardial infarction (MI). Using the Heart …

Objectives: We evaluated the effects of long-term therapy with the angiotensin-converting
enzyme (ACE) inhibitor ramipril on major cardiovascular (CV) outcomes in high-risk women …

Background—The HOPE study has demonstrated that ramipril is beneficial (ie, prevents
cardiovascular death, myocardial infarction, and stroke) for a broad range of patients without …

Background Angiotensin-converting–enzyme inhibitors improve the outcome among
patients with left ventricular dysfunction, whether or not they have heart failure. We assessed …

Background: The Heart Outcomes Prevention Evaluation (HOPE), a Canadian-led,
multicentre, randomized controlled trial, demonstrated the effectiveness of the ACE inhibitor …

The Heart Outcomes Prevention Evaluation (HOPE) study found that the ACE inhibitor
ramipril can lower the risk of atherosclerotic disease events and death in patients without …

Background—ACE inhibitor therapy reduces the risk of cardiovascular death, myocardial
infarction, stroke, hospitalization for heart failure, and need for revascularization in high-risk …

Background Angiotensin-converting-enzyme inhibitors improve the outcome among patients
with left ventricular dysfunction, whether or not they have heart failure. We assessed the role …

Background—Previous trials in the prevention of heart failure have been restricted to
patients with low ejection fraction or hypertension. We assessed an angiotensin-converting …

The HOPE study was a 19 country, prospective randomized trial in which the ACE‐inhibitor
Ramipril but not Vitamin E significantly reduced the risk of future cardiovascular events in a …